Normal Pressure Hydrocephalus as ME/CFS “Micro-NPH” Parallel
Certainty: 0.35.
Normal pressure hydrocephalus (NPH) presents with the triad of gait disturbance, cognitive impairment, and urinary incontinence—symptoms that overlap extensively with ME/CFS, particularly the cognitive dysfunction (“brain fog”) and fatigue. NPH is diagnosed by CSF dynamics abnormalities and treated effectively by CSF shunting or lumbar puncture drainage—essentially a “reduce CSF volume” intervention. In thousands of documented cases, CSF drainage (via shunt or tap test with temporary removal of 20–30 mL) produces dramatic cognitive recovery, often within days to weeks. This provides a proof-of-concept that reducing CSF volume can improve cognitive function in patients with CSF dynamics impairment.
ME/CFS could be conceptualized as “micro-NPH”—CSF dynamics impairment below the resolution threshold of standard imaging, where ventriculomegaly is not visible but CSF turnover is inadequate. The NIH deep phenotyping study identified reduced CSF catecholamines (dopamine, norepinephrine, epinephrine metabolites) in ME/CFS CSF (Walitt et al. 2024), with follow-up demonstrating selective central noradrenergic (not dopaminergic) deficiency (Aregawi et al. 2026), suggesting CSF neurochemical dysfunction that could impair glymphatic clearance or signaling. Smith and Verkman (2018) critique the glymphatic bulk flow hypothesis (Smith and Verkman 2018), arguing that tracer spread may reflect diffusion rather than convection—this criticism actually supports a “CSF dynamics only” model: if bulk flow is limited, enhancing turnover becomes critical, which is precisely what CA inhibitors achieve by reducing production.
Clinical implications. The NPH literature provides well-characterized outcome measures (gait speed, cognitive test batteries, urodynamic studies) that ME/CFS research could adapt. If ME/CFS cognitive symptoms reflect inadequate CSF turnover rather than inflammation or neurodegeneration, then a subset of patients should respond to CSF drainage strategies. This predicts that: (a) ME/CFS patients with brain-fog–predominant phenotype and no structural CSF obstruction (normal ventricles on MRI) may benefit from diagnostic lumbar puncture with removal of 20–30 mL (tap test analog), producing measurable cognitive improvement; (b) Phase-contrast MRI CSF flow studies will show reduced aqueductal CSF stroke volume and slower perivascular diffusion in responders; (c) ONSD diurnal pattern (Section Overnight ONSD Change as Non-Invasive Glymphatic Biomarker) will normalize with successful drainage.
Key distinctions from classical NPH. In NPH, ventriculomegaly is visible on MRI; in ME/CFS, ventricular size may be normal, suggesting the impairment is functional (turnover dynamics) rather than anatomical obstruction. CSF opening pressure may be normal or only mildly elevated in ME/CFS, whereas NPH patients typically have higher pressures (>25 cm H2O). This suggests that ME/CFS may involve a milder form of CSF dynamics disorder that is nonetheless functionally significant due to neurochemical sensitivity (reduced catecholamines) or glymphatic AQP4 dysfunction.
Testable predictions.
- ME/CFS patients with brain-fog–predominant phenotype will show improvement in processing speed, executive function, and working memory after diagnostic lumbar puncture with 20–30 mL CSF removal, mirroring NPH cognitive recovery
- Phase-contrast MRI in these patients will show reduced aqueductal CSF stroke volume and increased CSF pulsatility compared to baseline, indicating improved CSF turnover
- ME/CFS patients with normal ventricles on MRI will respond equally well to CSF drainage as NPH patients with ventriculomegaly, provided CSF turnover is the limiting factor
- Patients with documented intracranial hypertension signs (opening pressure >25 cm H2O, papilledema) will show larger cognitive benefit from CSF drainage than patients with normal pressures, predicting that elevated ICP is a positive predictor of response
- Combining CSF drainage with existing ME/CFS treatments (Perrin Technique, sleep optimization) will produce additive cognitive benefit in responder subgroup
The hypotheses in this chapter—metabolic “safe mode,” glymphatic impairment, synergistic CSF drainage, sequential therapy, overnight ONSD monitoring, and micro-NPH—share a common epistemic limitation: each is internally consistent and mechanistically plausible, but none has been directly tested in ME/CFS patients. Key boundaries:
- No prospective study has demonstrated that any of these mechanisms precedes or causes ME/CFS; all are inferred from cross-sectional data, analogy to other diseases, or theoretical modeling.
- The “safe mode” / “locked sickness behavior” framing is a narrative organizing device, not an empirically validated construct; identical language could be applied post hoc to any chronic illness with inflammatory features.
- Testable predictions listed for each hypothesis are necessary but not sufficient: confirmation of individual predictions would support but not prove the overarching model, as alternative mechanisms could generate the same observations.
- Several hypotheses (HERV reactivation, purinergic quorum sensing, MCT dysfunction) rest on phenomena demonstrated in cell lines or animal models that have not been measured in ME/CFS cohorts at all.